(262) Preparation of Rivaroxaban Dry Powder for Inhalation Using a Two-Step Milling Process

Introduction: Rivaroxaban (RVX) is a direct oral anticoagulant (DOAC) recommended as a first-line treatment for pulmonary embolism (PE). While RVX offers superior clinical benefits over low-molecular-weight heparin (LMWH), it carries a higher risk of major bleeding, highlighting the need for research into low-dose administration strategies.This study aims to develop an inhalable dry powder inhaler (DPI) formulation of RVX to enhance bioavailability (BA), achieve a rapid onset of action, and reduce systemic side effects through low-dose administration.